NCT03685591: PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only patients with HR+/HER2-neg breast cancer will be eligible for Part 2; Patients must have progressed on prior CDK4/6 inhibitor therapy & received greater than or equal to 2 prior lines of therapy in the metastatic setting
Exclusions: Patients with liver metastases, CNS metastases, carcinomatous meningitis, or leptomeningeal disease; Patients with a history of CNS metastases or cord compression.
https://ClinicalTrials.gov/show/NCT03685591

Comments are closed.

Up ↑